These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 15570079)

  • 1. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
    Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
    J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
    Prados MD; Yung WK; Fine HA; Greenberg HS; Junck L; Chang SM; Nicholas MK; Robins HI; Mehta MP; Fink KL; Jaeckle KA; Kuhn J; Hess KR; Schold SC;
    Neuro Oncol; 2004 Jan; 6(1):33-7. PubMed ID: 14769138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
    Brandes AA; Tosoni A; Cavallo G; Bertorelle R; Gioia V; Franceschi E; Biscuola M; Blatt V; Crinò L; Ermani M;
    Br J Cancer; 2006 Nov; 95(9):1155-60. PubMed ID: 17024124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
    Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
    Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Franceschi E; Blatt V; Santoro A; Faedi M; Amistà P; Gardiman M; Labianca R; Bianchini C; Ermani M; Reni M
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):769-75. PubMed ID: 19169684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
    Barrié M; Couprie C; Dufour H; Figarella-Branger D; Muracciole X; Hoang-Xuan K; Braguer D; Martin PM; Peragut JC; Grisoli F; Chinot O
    Ann Oncol; 2005 Jul; 16(7):1177-84. PubMed ID: 15857844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
    Chinot OL; Barrié M; Fuentes S; Eudes N; Lancelot S; Metellus P; Muracciole X; Braguer D; Ouafik L; Martin PM; Dufour H; Figarella-Branger D
    J Clin Oncol; 2007 Apr; 25(12):1470-5. PubMed ID: 17442989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
    Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Vredenburgh J; Gururangan S; Provenzale JM; Walker A; Schweitzer H; Bigner DD; Tourt-Uhlig S; Herndon JE; Affronti ML; Jackson S; Allen D; Ziegler K; Bohlin C; Lentz C; Friedman HS
    Neuro Oncol; 2004 Apr; 6(2):145-53. PubMed ID: 15134629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Sampson JH; McLendon RE; Herndon JE; Friedman HS
    J Neurooncol; 2009 Dec; 95(3):393-400. PubMed ID: 19533023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
    Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
    Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Franceschi E; Cavallo G; Lonardi S; Magrini E; Tosoni A; Grosso D; Scopece L; Blatt V; Urbini B; Pession A; Tallini G; Crinò L; Brandes AA
    Br J Cancer; 2007 Apr; 96(7):1047-51. PubMed ID: 17353924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.